Is Naxitamab injection on the market?

Naxitamab injection (Naxitamab) is a humanized (IgG1) antiGD2 (hu3F8) monoclonal antibody developed by Memorial Sloan-Kettering Cancer Center (commercially licensed to Y-mAbs therapeutics Inc.) for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers.

Nasitumumab injection received accelerated approval from the U.S. Food and Drug Administration (FDA) in November 2020 for the treatment (in combination with granulocyte-macrophage colony-stimulating factor) of pediatric patients at least one year old and adult patients with relapsed or refractory high-risk neuroblastoma of the bone or bone marrow who have demonstrated partial response, minor response, or stable disease to previous treatment. On days 1, 3, and 5 of each treatment cycle, the recommended dose of nacituzumab injection is 3 mg/kg/day (up to 150 mg/day), diluted and combined with GM-CSF for intravenous infusion, and subcutaneously injected at 250g/m2/day on days 4-0 and 500g/m2/day subcutaneously on days 1-5. Treatment cycles are repeated every 4 to 8 weeks.

It is understood that nocetumumab injection has been approved in China through the relevant standards of the National Medical Products Administration in November 2022, but it has not yet been included in medical insurance. Its price is still unclear and the purchase method is difficult. The original drug of nascituzumab injection marketed overseas is very expensive, and the price may fluctuate due to exchange rates. For more drug information and specific prices, please consult a medical consultant.